Bloomberg: CVS-Aetna deal close to clearing antitrust process

CVS Health’s takeover of health insurance giant is likely close to clearing the antitrust process with the Department of Justice, Bloomberg reported last week.

The deal, which is valued at approximately $69 billion, has come under fire recently over concerns of declining market competition and consumer choice.

CVS officials were confident the deal would move forward during the company’s most recent quarterly earnings call with analysts, and even specified when they expect the transaction to close–a sign that the deal will win approval of federal regulators, according to Bloomberg.

Read the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Trimed Popup
Trimed Popup